Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Overall survival: RRSO alone vs RRSO and RRM Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Overall survival: RRSO and RRM vs no RRSO Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.14 [0.02, 0.98] | 1 study · 261 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Breast cancer mortality: RRSO alone vs RRSO and RRM Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Breast cancer mortality: RRSO and RRM vs no RRSO Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 1 study · 722 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Bone fracture incidence Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO HGSC mortality: BRCA1 or BRCA2 Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.06 [0.02, 0.17] | 3 studies · 2534 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Severe adverse events Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Overall survival Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO HGSC mortality Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Breast cancer mortality: ≤ 50 years Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.78 [0.55, 1.09] | 3 studies · 4566 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Breast cancer mortality: > 50 years Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 1.27 [0.67, 2.38] | 3 studies · 4566 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Bone fracture incidence Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Severe adverse events Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Overall survival Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO HGSC mortality Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Breast cancer mortality: ≤ 50 years Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.49 [0.08, 2.9] | 2 studies · 444 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Breast cancer mortality: BRCA1 or BRCA Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.58 [0.39, 0.88] | 7 studies · 7198 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Breast cancer mortality: > 50 years Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 1.36 [0.68, 2.75] | 2 studies · 444 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Bone fracture incidence Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Severe adverse events Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Bone fracture incidence Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Quality of life (ovarian cancer risk perception): BRCA1 or BRCA2 Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 1 study · 200 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Quality of life (breast cancer risk perception): BRCA1 or BRCA2 Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 1 study · 200 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO Severe adverse events Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status Overall survival: BRCA1 only Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.3 [0.17, 0.52] | 3 studies · 2548 participants | Very low |
Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status Overall survival: BRCA2 only Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations (2018) · Cochrane | HR 0.44 [0.23, 0.85] | 2 studies · 2122 participants | Very low |
Summary of findings: Conformal RT vs conventional RT Mean GI symptom scores · People with urological (prostate) gynaecological (cervical) cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | 0 participants | Ungraded |
Summary of findings: BT vs EBRT Acute and late GI toxicity (grade 2+) · People with urological (prostate) and gynaecological (endometrial) cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Probiotics vs control (placebo or no intervention) Diarrhoea (grade 2+) · People undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | RR 0.43 [0.22, 0.82] | 5 studies · 923 participants | Low |
Summary of findings: Probiotics vs control (placebo or no intervention) QOL scores · People undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Proteolytic enzymes vs control (placebo or no intervention) Mean GI symptom scores · People undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Proteolytic enzymes vs control (placebo or no intervention) Acute and late GI toxicity (grade 2+) · People undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | RR 0.45 [0.24, 0.88] | 1 study · 120 participants | Low |
Summary of findings: Proteolytic enzymes vs control (placebo or no intervention) Diarrhoea (grade 2+) · People undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | RR 1.6 [0.89, 2.89] | 1 study · 56 participants | Very low |
Summary of findings: Proteolytic enzymes vs control (placebo or no intervention) QOL scores · People undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Glutamine vs placebo Mean GI symptom scores · People undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Glutamine vs placebo Acute and late GI toxicity (grade 2+) · People undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | RR 2.4 [0.68, 8.53] | 1 study · 69 participants | Low |
Summary of findings: Glutamine vs placebo Diarrhoea (grade 2+) · People undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | RR 0.98 [0.78, 1.24] | 4 studies · 289 participants | High |
Summary of findings: Glutamine vs placebo QOL scores · People undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: BT vs EBRT Diarrhoea (grade 2+) · People with urological (prostate) and gynaecological (endometrial) cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | 0 participants | Ungraded |
Summary of findings: Counselling vs no intervention Mean GI symptom scores (lower is better) · Individuals undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | MD 0.08 | 1 study · 152 participants | Low |
Summary of findings: Counselling vs no intervention Acute and late GI toxicity (grade 2+) · Individuals undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Counselling vs no intervention Diarrhoea (grade 2+) · Individuals undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | RR 0.12 [0.03, 0.47] | 1 study · 74 participants | Low |
Summary of findings: Counselling vs no intervention QOL scores (5‐point VAS; lower is better) · Individuals undergoing RT for pelvic cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | 1 study · 152 participants | Very low |
Summary of findings: BT vs EBRT QoL scores (EORTC Q30) · People with urological (prostate) and gynaecological (endometrial) cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | 1 study · 348 participants | Ungraded |
Summary of findings: Reduced dose volume vs standard dose volume Mean GI symptom scores · People undergoing RT for pelvic cancer1 Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Reduced dose volume vs standard dose volume Acute and late GI toxicity (grade 2+) · People undergoing RT for pelvic cancer1 Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | RR 1.21 [0.81, 1.81] | 1 study · 211 participants | Moderate |
Summary of findings: Reduced dose volume vs standard dose volume Diarrhoea (grade 2+) · People undergoing RT for pelvic cancer1 Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Reduced dose volume vs standard dose volume QOL scores · People undergoing RT for pelvic cancer1 Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Higher bladder volume vs lower bladder volume Mean GI symptom scores (during RT) · Men undergoing RT for prostate cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Higher bladder volume vs lower bladder volume Acute and late GI toxicity (grade 2+) · Men undergoing RT for prostate cancer Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary… (2018) · Cochrane | RR 2.22 [0.62, 7.93] | 1 study · 110 participants | Low |